Azinomycins A and B, new antitumor antibiotics. III. Antitumor activity.
Azinomycins A and B, isolated from the culture broth of Streptomyces griseofuscus S 42227, were examined for antitumor activities against P388 leukemia, P815 mastocytoma, B-16 melanoma, Ehrlich carcinoma, Lewis lung carcinoma and Meth A fibrosarcoma. Azinomycin B was markedly effective against the intraperitoneally inoculated tumors such as P388 leukemia, B-16 melanoma and Ehrlich carcinoma. The intraperitoneal administration of azinomycin B showed 57% survivors for 45 days and 193% ILS against P388 leukemia. For Ehrlich carcinoma, azinomycin B gave 161% ILS and 63% survivors for 45 days, but solid tumors such as Lewis lung carcinoma and Meth A fibrosarcoma were not susceptible to repeated injection of this substance. Azinomycin A was somewhat less effective than azinomycin B for the tumor systems tested.
D000818:Animals; D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D053961:Azabicyclo Compounds; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D004151:Dipeptides; D004353:Drug Evaluation, Preclinical; D005354:Fibrosarcoma / Q000188:drug therapy; D006020:Glycopeptides / Q000627:therapeutic use; D036341:Intercellular Signaling Peptides and Proteins; D007941:Leukemia P388 / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D012515:Mast-Cell Sarcoma / Q000188:drug therapy; D008546:Melanoma, Experimental / Q000188:drug therapy; D051379:Mice; D016685:Mitomycin; D008937:Mitomycins / Q000627:therapeutic use; D009281:Naphthalenes; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D010455:Peptides; D013329:Structure-Activity Relationship
D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic; D053961:Azabicyclo Compounds; D004151:Dipeptides; D006020:Glycopeptides; D036341:Intercellular Signaling Peptides and Proteins; D008937:Mitomycins; D009281:Naphthalenes; D010455:Peptides; C051055:azinomycin B; C051054:azinomycin A; D016685:Mitomycin